-250 -200 -150 -100 -50 0 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg -250 -200 -150 -100 -50 0 0 4 8 12 16 20 24 All KSI-101 APEX KSI-101 in DME – Meaningful anatomical gains were achieved with all KSI-101 dose levels tested 68 Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes all available data by the 14-Jul-25 cutoff date. Bioactivity was observed in all dose levels, with an apparent additional benefit obtained with the highest KSI-101 dose level (10 mg) Microns Weeks Treatment Phase Off-treatment Phase N values 2.5 mg 4 4 4 4 4 4 4 4 5 mg 4 4 4 3 3 3 3 3 10 mg 4 4 4 4 4 4 4 3 N values All KSI-101 12 12 12 11 11 11 11 10 Microns Weeks Mean Change in OCT CST by KSI-101 dose level Mean Change in OCT CST all KSI-101 dose levels combined Treatment Phase Off-treatment Phase